This review assessed the effects of bisphosphonates on bone mineral density following total joint arthoplasty. The authors concluded that studies suggest that bisphosphonates maintain periprosthetic bone better than a control, but further research is required to assess clinical outcomes. This was a well-conducted review and the authors' cautious conclusions reflect the evidence.
independently assessed validity and resolved any disagreements through discussion. The assessment of validity was sent to each corresponding author for verification. Inter-reviewer agreement was assessed using the kappa statistic.
Data extraction
One reviewer extracted the data and checked the accuracy. The data extraction was sent to each corresponding author for verification. The data extracted included the number of patients in each treatment group, the baseline BMD, and study outcomes extracted as the difference between treatments in the BMD at 3, 6 and 12 months. Values for BMD were extrapolated from graphs where required. For each study, the mean difference in BMD between treatments was calculated with the 95% confidence intervals (CIs).
Methods of synthesis
How were the studies combined? Pooled weighted mean differences (WMDs) with 95% CIs between treatments were calculated. A funnel plot was used to assess publication bias.
How were differences between studies investigated?
Statistical heterogeneity was assessed using methods described by Hedges and Olkin (with a significance level of P<0.1). The influence of the following predefined factors was examined: type of arthroplasty (with or without cement); region (knee or hip); type of bisphosphonate; and study quality (less than 70 or 70 or more points). WMDs in BMD were calculated for all these subgroups.
Results of the review
Six RCTs (n=264) were included. The sample size ranged from 13 to 96 patients.
Inter-rater agreement was good for both study selection (kappa 0.85) and study quality (kappa 0.88).
In terms of study quality, 2 studies were blinded. There was complete follow-up in 4 studies.
Three studies assessed BMD at 3 months after surgery and all showed a decrease in both treatment groups.
There was significantly less periprosthetic bone loss at 3 months with bisphosphonates compared with the control; the WMD (n=152) was 3.3% (95% CI: 1.9, 4.7, P<0.01). The difference remained statistically significant at 6 and 12 months; the WMDs were 4.5% (5 studies, n=248; 95% CI: 1.6, 7.4, P<0.001) and 4.2% (4 studies, n=197; 95% CI: 1.5, 6.9, P=0.02), respectively.
Neither the type of bisphosphonate nor the quality score significantly altered the results.
The difference between bisphosphonate and control was significantly greater at 12 months (P<0.001) for cemented hip arthroplasties (WMD 7.5%, 95% CI: 4.3, 10.7) compared with uncemented hip arthroplasties (WMD 2.1%, 95% CI: 0.61, 3.6), but the results might have been confounded by the greater age of patients undergoing cemented arthoplasties (68 years for cemented versus 55 years for uncemented).
The difference between bisphosphonate and control was significantly greater at 6 months (P<0.001) for total knee arthroplasties (WMD 14.0%, 95% CI: 6.3, 21.7) compared with total hip arthroplasties (WMD 2.5%, 95% CI: 0.96, 4.1), but the difference was not statistically significant at one year.
The funnel plots showed no evidence of publication bias at 3, 6 or 12 months.
